Small molecules that activate JMJD3 or promote the interaction of JMJD3 with SIRT1 specifically decreased the lipid levels, which may provide a therapeutic approach to treat obesity and hepatosteatosis [70]. This evidence concerns the gene KDM6B and obesity disorder.